Optimize Your Process For Producing High-Concentration Drugs

The number of monoclonal antibodies (mABs) formulated at high concentrations is projected to increase annually by 13% from 2024 to 2029. This anticipated growth in demand poses unique challenges for drug manufacturing. Due to lower production volumes, every drop of the product becomes incredibly valuable to necessitate maximized product recovery. During this webinar, we will delve into the various challenges and practical solutions associated with high-concentration drug manufacturing processes. We will cover the entire spectrum, from tangential flow filtration (TFF) to the use of filling needles. A case study will be presented that focuses on the development of a high-concentration process exceeding 200 g mAb/L.

Discover strategies that enhance your product recovery and streamline production methods to improve your manufacturing of high-concentration drugs.